203 filings
10-K
2023 FY
OVID
Ovid Therapeutics Inc
Annual report
8 Mar 24
8:24am
8-K
OVID
Ovid Therapeutics Inc
8 Mar 24
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
8:20am
8-K
OVID
Ovid Therapeutics Inc
6 Dec 23
Other Events
5:08pm
EFFECT
OVID
Ovid Therapeutics Inc
16 Nov 23
Notice of effectiveness
12:15am
424B5
OVID
Ovid Therapeutics Inc
15 Nov 23
Prospectus supplement for primary offering
4:11pm
CORRESP
mq8acrqar5
13 Nov 23
Correspondence with SEC
12:00am
UPLOAD
ynqf9t7
8 Nov 23
Letter from SEC
12:00am
8-K
1vh6uqxedpbx1
3 Nov 23
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
8:10am
8-K
ywzp2ihejcz kqy
18 Oct 23
Ligand will receive 13% of all soticlestat royalties and milestone payments owed to Ovid
8:04am
8-K
987664woyxtwd u6
2 Oct 23
Dawn of the neurotherapeutics era Dr. Jeremy Levin CEO & Chairman
12:15pm
8-K
kee1p84alv
4 Aug 23
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
9:10am
8-K
z3h8dkyaydm
9 Jun 23
Submission of Matters to a Vote of Security Holders
8:54am
S-8
ezf m0m9y8o3
5 May 23
Registration of securities for employees
5:29pm
8-K
s5g1r5xsx5
5 May 23
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
8:16am
8-K
7izfynmw3j m19
1 May 23
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
4:17pm
8-K
fohfltk9qe8dwd8zp1b
27 Apr 23
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
4:43pm